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Alzheimer’s disease (AD) is the most common form of dementia, afflicting more than 30 million people worldwide.
Currently, there is no cure or way to prevent this devastating disease. Extracellular plaques, containing various forms
of amyloid-β protein (Aβ), and intracellular neurofibrillary tangles (NFTs), composed of hyper-phosphorylated tau
protein, are two major pathological hallmarks of the AD brain. Aggregation, deposition, and N-terminal modification
of Aβ protein and tau phosphorylation and aggregation are thought to precede the onset of cognitive decline,
which is better correlated with tangle formation and neuron loss. Active and passive vaccines against various forms
of Aβ have shown promise in pre-clinical animal models. However, translating these results safely and effectively
into humans has been challenging. Recent clinical trials showed little or no cognitive efficacy, possibly due to the
fact that the aforementioned neurodegenerative processes most likely pre-existed in the patients well before the
start of immunotherapy. Efforts are now underway to treat individuals at risk for AD prior to or in the earliest stages
of cognitive decline with the hope of preventing or delaying the onset of the disease. In addition, efforts to
immunize against tau and other AD-related targets are underway.
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Alzheimer’s disease: a brief introduction
Alzheimer’s disease afflicts 1 in 9 elderly individuals, and
accounts for dementia in more than 5.2 million Americans
and more than 30 million people worldwide [1]. The cost
for AD care is enormous, with an estimated sum of $200
billion in the USA alone last year. Currently, there is
no disease-modifying cure or prevention for AD. The
build-up of amyloid-β aggregates, possibly due to
slowed clearance, leads to Aβ plaque deposition and
vascular amyloid in neocortex and hippocampus years
to a decade or more before the onset of clinical symptoms
[2]. Subsequently, there is a rise in NFTs and neuron
loss that correlates with mild changes in memory. As the
pathology progresses, the cognitive impairment becomes
more severe, leading to full-blown dementia.
The identification of rare genetic mutations in the
amyloid precursor protein (APP), and the presenilins
(PS1, PS2), as well as Trisomy 21 (Down syndrome, DS),
that invariably lead to AD pathogenesis support theCorrespondence: clemere@partners.org
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reproduction in any medium, provided the orhypothesis that Aβ is an early, key player in the disease [3].
As such, a number of therapeutic strategies targeting Aβ
and its downstream consequences are under investigation.
These include inhibition or modulation of Aβ-generating
proteases by small molecules or immunotherapy, prevention
of Aβ aggregation and promotion of Aβ clearance by Aβ
immunotherapy, and interference of the toxic response to
Aβ by neurons by tau immunotherapy.Active versus passive immunization: advantages and
disadvantages
Active and passive immunotherapies are currently under
investigation for AD. While both strive to slow or prevent
cognitive decline, each has its own advantages and
disadvantages [4]. Active vaccination, for example, engages
the cellular and humoral immune system, including T cells
and B cells, to promote the production of anti-antigen
antibodies. Typically, an active vaccine is comprised of
an antigen (alone or conjugated to a non-self T helper
cell epitope) combined with an immune boosting adjuvant
to ensure high antibody titers. On one hand, active
immunotherapy is attractive because it can induce
long-term antibody production in a large population,This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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visits. However, an active vaccine also induces a T cell
response that can increase the risk of a deleterious
immune response (i.e., release of pro-inflammatory
cytokines), especially, if the T cell recognizes the antigen
as a self-protein. And, it takes time to “shut off” an active
vaccine immune response. An active vaccine leads to a
polyclonal antibody response, which means that it
generates antibodies recognizing multiple, sometimes
overlapping epitopes on the target protein. This may
be helpful for broad coverage or, it may be less useful
if the goal is to lower a specific form of a protein but
not all forms.
Passive immunotherapy involves the direct injection of
monoclonal antibodies (or fragments thereof ) without
requiring the immune system to generate an antibody
response. Several benefits of passive immunotherapy are
that it can be stopped immediately if there are any
adverse reactions and, that one can target specific epitopes
or pathogenic conformations without disturbing the
other forms of the protein of interest. On the downside,
passive immunization typically requires the production
of expensive humanized monoclonal antibodies and
monthly injections in a doctor’s office, thereby making it
less feasible for long-term treatment of a large population
compared to active immunization. In addition, repeated
dosing with antibodies over time may lead to the for-
mation of anti-antibodies, which could potentially have
a neutralizing effect and/or lead to side effects such as
glomerulonephritis and vasculitis.
Active Aβ immunotherapy
In the mid-1990’s, Beka Solomon’s lab first suggested that
anti-Aβ could be used to prevent Aβ fibril formation and
disaggregate pre-formed fibrils [5,6]. In 1999, Schenk and
colleagues at ELAN Pharmaceuticals demonstrated in vivo
that active immunization against full-length Aβ with an
adjuvant reduced plaque burden in an AD transgenic (Tg)
mouse model [7]. Subsequent studies, including our own,
demonstrated that active Aβ immunization generates
anti- Aβ antibodies that bind human plaques and have
B cell epitopes within the first 15 amino acids of the
Aβ peptide while the T cell epitopes resided within the
mid-region and C-terminus of Aβ [reviewed in 4]. Active
and passive Aβ immunotherapy in AD Tg mice were
shown to reduce cerebral Aβ and improve cognition,
especially if given before the onset of disease pathology
(i.e., prophylactically).
The first active vaccine clinical trial for AD, AN1792,
was halted early in 2002 due to the development of
meningoencephalitis in ~6% (18 of 300) of the enrolled
moderate-to-severe AD patients [8]. AN1792 was
comprised of full-length Aβ1-42 peptide formulated in
a strong adjuvant (QS-21; saporin) and polysorbate 80to increase solubility of the Aβ1-42 peptide and improve
the stability of the vaccine. Most patients received 1–3
doses; approximately 19% made anti- Aβ antibodies
(>1:2,000 titer; “responders”) that bound AD plaques
and vascular amyloid in human brain sections. While Aβ
deposition was reduced focally in specific brain regions in
the small number of responders that came to autopsy over
the next several years, many were severely demented at
the time of death [9], indicating that removal of plaques
during late stage AD pathogenesis, after the formation of
NFTs and the rampant region-specific loss of neurons,
was not beneficial. Interestingly, tau aggregates in neuropil
threads and dystrophic neurites, often associated with
plaques, were reduced by AN1792 vaccination but no
changes were observed in tau accumulation within
neuronal cell bodies [10]. The exact cause of the men-
ingoencephalitis in the AN1792 trial is unknown, however,
possible causes might include the recognition of the
antigen (full-length Aβ peptide) by Aβ-specific T cells, the
strong Th1-biased adjuvant, or possibly, the re-formula-
tion of the vaccine with polysorbate 80.
As a result of the AN1792 trial, a large effort was
undertaken to test passive immunotherapy using human-
ized anti- Aβ monoclonal antibodies (mAb), as described in
the next section, to avoid any autoimmune-like reactions.
In addition, studies were initiated to develop second-
generation active vaccines, including many vaccines that
target an Aβ B cell epitope, while avoiding Aβ T cell
epitopes. These include mimotopes vaccines, neoepitopes
vaccines, Aβ-conjugates, and DNA, phage, virus-like
particle and adenovirus-associated viral vector vaccines
[reviewed in 4].
Currently, several second-generation active Aβ vaccines
are being tested in clinical trials (www.clinicaltrials.gov).
Janssen and Pfizer are conducting Phase II studies to
monitor the effects of their Aβ short N-terminus peptide-
conjugate vaccine called ACC-001, formulated in the
adjuvant QS-21 [11]. Last year, Novartis Pharmaceuticals
reported Phase I data for their active Aβ vaccine,
CAD106, which consists of multiple copies of Aβ1-6 on
QB virus-like particles with or without adjuvant [12].
Phase II CAD106 clinical trials were completed recently
and the data analyses are pending. Affiris AG is testing
mimotopes, molecular mimics of specific antigen epitopes,
against an unmodified Aβ N-terminus (Phase II) and a
pyroglutamate-3-modified Aβ N-terminus (Phase Ib) [13].
AC Immune is continuing their combined Phase I/IIa
clinical trial to investigate ACI-24, an active Aβ vaccine
intended to induce beta-sheet conformation-specific
antibodies, similar to a liposomal vaccine against Aβ1-15
that they previously showed in preclinical studies reduced
plaques and restored memory [14]. The main goal of these
active vaccines is to prevent plaque deposition and/or
enhance Aβ clearance.
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In 2000, Bard and colleagues first demonstrated that
systemic injection of an Aβ monoclonal antibody specific
for the Aβ N-terminus, 3D6 mAb, into AD Tg mice
resulted in transfer of the antibody into brain, binding
of the antibody to plaques, and induction of Fc-receptor-
mediated microglial phagocytosis of Aβ deposits [15].
This antibody is the precursor to the humanized N-
terminal-specific mAb, Bapineuzumab, which went on
to be tested in Phase I, II and III clinical trials. While
Bapineuzumab was shown to lower Aβ burden in brain
by in vivo amyloid PET imaging in a Phase II trial in
mild-to-moderate AD patients [16], no significant clinical
benefits have been reported in 2 large Phase III clinical
trials, according to www.clinicaltrials.gov, leading to the
termination of other Phase III Bapi trials in 2012. Two
possibilities for the lack of clinical efficacy of Bapi in-
clude the possibility that not enough antibody made it
into the brain and/or that the treatment was too late in
the disease process to reverse the neurodegenerative
changes that underlie memory loss. Earlier intervention
with Aβ immunotherapy may help clarify these points.
According to www.clinicaltrials.gov, Pfizer and Janssen
are currently conducting an Open Label Extension
Phase I clinical study in mild-moderate AD patients to
test the safety and tolerability of a more recent version
of Bapineuzumab, AAB-003, that was re-engineered to
reduce the risk of vasogenic edema and microhemorrhage.
Other Aβ mAbs, targeting epitopes in the N-terminus,
mid-region, and C-terminus, as well as conformation-
specific mAbs, have been tested pre-clinically for their
ability to prevent or lower plaque burden and improve
cognition [reviewed in 4]. In 2002, Pfeifer et al., reported
that repeated administration of an Aβ mAb that recog-
nized Aβ3-6 in old APP23 Tg mice with a high vascular
amyloid load resulted in plaque lowering but also signifi-
cantly increased the number of cerebral microhemorrhages
[17]. This was confirmed in other preclinical studies in
AD Tg mice [18,19]. Treatment with Bapineuzumab has
been associated with transient vasogenic edema and
microhemorrhage, especially in AD patients bearing one
or two Apolipoprotein E ε4 alleles [20].
In 2001, DeMattos and colleagues reported that a
mid-region Aβ mAb, that preferentially binds soluble
Aβ (m266) lowered brain Aβ burden and increased Aβ
levels in plasma, suggesting that the antibodies enhanced
clearance from brain to blood [21]. A single injection of
m266 mAb was reported to improve cognition within a
few days in 2 year-old AD Tg mice [22]. The m266 mAb is
the precursor to Lilly’s Solanezumab that is currently
in Phase III clinical trials. Solanezumab has not been
associated with vasogenic edema or microhemorrhages but
does increase plasma Aβ [23]. Recently, Lilly announced
that 18 months of treatment with Solanezumab significantlyslowed cognitive decline in mild AD patients when they
combined cohorts from 2 Phase III studies [24].
Based on the aforementioned clinical trial results, most
new Aβ passive trials are focused on prevention and very
early treatment of AD. Genentech, the Banner Institute
and the National Institutes of Health have partnered to
conduct a secondary prevention trial called API (the
Alzheimer’s Prevention Initiative) in 300 individuals
from a large Colombian family with a mutant gene
(PS1 E280A) associated with a dominant form of early
onset Alzheimer’s disease. This mutation leads to early
and robust cerebral Aβ42 plaque deposition at a relatively
young age [25], which is followed within 10–15 years by a
progressive decline in cognition and clinical function [26].
Participants 30 years of age and older will be included
in this prevention study that will test Genentech’s
Crenezumab mAb, licensed from AC Immune. Crenezu-
mab is a humanized Aβ mAb that binds soluble, oligomeric
and fibrillar Aβ but unlike the other antibodies tested thus
far, Crenezumab was designed on an IgG4 backbone to
reduce the risk of microglial-mediated pro-inflammatory
effects in brain, including vasogenic edema [27]. The study
is expected to begin in 2013.
Other prevention/early treatment trials are expected to
begin this year (2013). DIAN, the Dominantly Inherited
Alzheimer Network, will conduct a collaborative trial
between Lilly, Roche, and the Alzheimer’s Association,
in adult children of a parent with a familial Alzheimer’s
disease mutant gene that causes dominantly inherited
AD. Lilly’s Solanezumb mAb (described above) and
Roche’s mAb, Gantenerumab, will be tested. Gantenerumab,
which recognizes an epitope in the Aβ N-terminus and then
another in its mid-region and preferentially binds fibrillar
Aβ [28], is already in Phase III clinical trials in prodromal
AD subjects who are amyloid-positive by PET imaging
but not yet cognitively impaired. A third prevention
trial called A4, Anti-Amyloid Treatment for Asymptomatic
Alzheimer’s Disease, will test Solanezumab in 1,000 people
70 years of age and older, without a dominant genetic
predisposition to AD, who have positive PET scans for brain
amyloid but have not developed clinical AD symptoms.
Additional Aβ passive immunotherapies are also
currently under investigation. For example, Eisai Inc.
is conducting a large Phase II clinical trial in 800
patients with early AD to study the effects of an
Aβ mAb, BAN2401, that recognizes large oligomers
(called protofibrils) to try to prevent their toxic effects
on neurons. BAN2401 was developed by BioArtic
Neuroscience AB and licensed to Eisai in 2007. Biogen
Idec is also moving forward with their Aβ humanized
IgG1 mAb, BIIB037, that binds strongly to fibrillar Aβ in
plaques but less well to vascular amyloid (as reported by
Dr. Jeff Sevigny at the AD/PD International Conference,
Florence 2013). After a successful single ascending dose
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prodromal and mild AD patients who are being recruited
for a multiple dose Phase 1 study.
Pre-clinical studies have reported beneficial effects of
passive immunotherapy against other Aβ-related targets
as well. For example, pyroglutamate-3 Aβ is a highly
pathogenic Aβ species found in plaques and vascular
amyloid but not in CSF or plasma, that may act as a
seed for Aβ aggregation [29,30]. We reported that a
pyroglutamate-3 β mAb, 07/1, provided by our collabora-
tors at Probiodrug AG, reduced plaque burden in young
and old AD Tg mice, in the absence of increased vascular
amyloid or microhemorrhage [31]. Others have reported
similar findings [32,33]. Recently, we found that the
anti-pyroglu Aβ 07/1 mAb partially spared cognitive
deficits in an AD Tg mouse model (as reported by Jeff
Frost at the AD/PD Conference in Florence, Italy in
March 2013). It is likely that a pyroglutamate-3 Aβ mAb
will not get saturated by binding to Aβ in blood, thereby
potentially enhancing the transfer of the antibody into
brain to prevent Aβ deposition into plaques and blood
vessels and to enhance Aβ clearance.
Alternative AD immunotherapies: IVIg and tau
immunotherapy
Intravenous immunoglobulin (IVIg), pooled human anti-
bodies, showed promise in early (pilot and Phase II) clinical
trials reviewed in [34]. However, recent trials, including
Octapharma USA’s Phase II 24-week Octagam 10% IVIg
trial in 58 AD patients [35] and Baxter Healthcare Corpo-
ration’s large 18-month Phase III Gammagard 10% IVIg
trial in 390 mild-moderate AD [36] showed no significant
slowing of AD progression. As a result, Baxter has termi-
nated its IVIg program for Alzheimer’s disease. Ongoing
IVIg clinical trials include a small Phase II study of
Octagam by Sutter Health Neuroscience Institute in 50
MCI subjects and a Phase III study by Grifols Biologicals,
Inc. in which 350 mild-moderate AD subjects are being
treated with a combination of albumin and IVIg. Both
trials are due to be completed in 2014, according to
www.clinicaltrials.gov.
Lastly, the interest in tau immunotherapy for AD and
tau-relevant neurodegenerative diseases has grown
immensely over the past few years, perhaps in part,
due to the failure of Aβ IT to reverse cognitive deficits
in moderate-severe AD patients. At least 8 preclinical
reports have been published to date regarding the
beneficial effects of active and passive immunotherapy
targeting tau aggregates and/or tau phospho-epitopes in
tau Tg mouse models reviewed in [37]. Axon Neuroscience
SE (Graz, Austria) recently began recruiting mild-moderate
AD patients for a Phase I safety study of their new
AADvac1 tau-peptide-KLH-conjugate active vaccine,
formulated in alum (www.clinicaltrials.gov). It is likelythat other active as well as passive tau vaccines will be
forthcoming.
Challenges for future AD immunotherapies
While the field of AD immunotherapy has grown tremen-
dously over the past 10–13 years, certain issues still
remain and may need to be overcome in order to see
long-term, clinical safety and efficacy. First, more anti-
bodies, whether generated by active immunization or
administered passively, may need to get into the brain to be
effective. Typically, only a small percentage of antibodies
cross the blood brain barrier (~0.1%), thus it may be
helpful to find ways to improve antibody penetration into
brain. Some possibilities include: the use of chaperone
proteins or bi-specific antibodies to ferry the therapeutic
antibodies into brain, transient opening of the BBB by
chemical or radiological means, and direct infusion of
antibodies into the CNS using a time-released pump.
Second, removing amyloid after neurons are lost has
not been effective thus far, suggesting that treatment
should be started earlier and perhaps, should be tested
for longer periods of time. Such studies are now underway.
Third, a better understanding of the clearance of Aβ/
anti-Aβ immune complexes is needed to avoid clogging
of the clearance pathway during long-term treatment.
Active vaccination requires particular attention to immune
effects of immunotherapy, including immunosenescence
in the elderly, the potential for autoimmune effects when
vaccinating against self-proteins, and the use of strong,
pro-inflammatory adjuvants. Vaccine platforms that have
been shown to safely generate reasonable titers in the
elderly and immuno-compromised humans may be useful
for an AD vaccine. For example, we recently utilized
Mercia Pharmaceutical’s MER vaccine platform, which
was shown previously to safely generate titers against
self-proteins in two cancer vaccines, to test an Aβ1-15:
diptheria toxoid conjugate vaccine called MER5101,
which was formulated in an adjuvant, MAS-1, in an AD
transgenic mouse model. The vaccine generated high
titers and lowered plaques, induced an anti-inflammatory
immune response, and improved cognition [38]. And
lastly, improving the sensitivity of biomarkers, including
imaging of pre-amyloid diffuse plaques, and cognitive/
functional tests to detect the earliest changes in AD will
allow for better patient selection for clinical trials and
more sensitive outcome measures.
Conclusions
It is now well accepted that Alzheimer’s disease patho-
genesis begins years, if not decades, before the onset of
clinical symptoms. Aβ aggregation and accumulation, as
well as N-terminal truncation and modification, are very
early, region-specific events in AD. Genetics, CSF bio-
markers and imaging of brain structure and amyloid
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AD. Thus far, amyloid-lowering treatments (e.g., active
and passive Aβ immunotherapy) have shown little or no
cognitive benefit in moderate to severe AD patients, in
whom the disease process had been underway for years.
This suggests that removing amyloid cannot reverse
cognitive deficits once significant neuronal damage has
occurred. Instead, the aim now is to start Aβ immuno-
therapy at the onset of AD pathological changes, prior
to or in the very early stages of clinical symptoms, in
the hope of preventing downstream events, such as
neuroinflammation and tau pathology, that lead to neuron
loss and cognitive impairment. Tau immunotherapy,
especially vaccines targeting pathogenic forms of tau
protein, may be effective in slowing cognitive decline
once AD pathogenesis is underway and/or has manifested
in cognitive changes. Taken together, it remains possible
that with earlier detection and treatment, it may be
possible to prevent or delay Alzheimer’s disease in the
future. Considering the growing medical, economic,
and societal burden of AD, the need for an effective
treatment is stronger than ever.
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